Spotlight on Aggressive Non-Hodgkin Lymphomas (NHL)
We invite you to learn more about:
- Treatment options for aggressive subtypes of non-Hodgkin lymphoma (NHL)
- CAR T-cell therapy for aggressive lymphomas
- Side-effect management
- Questions to ask your healthcare team about treatment options and quality of life issues
Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas at MD Anderson Cancer Center
Houston, TX
Program Support
Support for this program is provided by Bristol Myers Squibb, Eli Lilly and Company, Genmab US & AbbVie Inc., Incyte Corporation, Kite, A Gilead Company, Merck & Company, and MorphoSys US.